Session

IBD (Posters)

TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE
TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE

IBD (Posters)  et al.

MUCUS COMPOSITION ALTERATIONS IN INFLAMMATORY BOWEL DISEASES (IBD)
MUCUS COMPOSITION ALTERATIONS IN INFLAMMATORY BOWEL DISEASES (IBD)

IBD (Posters)  et al.

TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

IBD (Posters)  et al.

INTESTINAL ULTRASOUND FEATURES ASSOCIATED WITH RESPONSE TO ADALIMUMAB IN PATIENTS WITH CROHN’S DISEASE
INTESTINAL ULTRASOUND FEATURES ASSOCIATED WITH RESPONSE TO ADALIMUMAB IN PATIENTS WITH CROHN’S DISEASE

IBD (Posters)  et al.

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL

IBD (Posters)  et al.

ROLE OF NOTCH PATHWAY IN CROHN'S DISEASE: IMPLICATIONS IN FIBROSIS
ROLE OF NOTCH PATHWAY IN CROHN'S DISEASE: IMPLICATIONS IN FIBROSIS

IBD (Posters)  et al.

COMPARATIVE ASSESSMENT C-REACTIVE PROTEIN BETWEEN A POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (IMMUNONEPHELOMETRIC TESTING)
COMPARATIVE ASSESSMENT C-REACTIVE PROTEIN BETWEEN A POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (IMMUNONEPHELOMETRIC TESTING)

IBD (Posters)  et al.

SAFETY OF VEDOLIZUMAB AND USTEKINUMAB IN ELDERLY IBD PATIENTS: A REAL-LIFE MULTICENTRIC COHORT STUDY
SAFETY OF VEDOLIZUMAB AND USTEKINUMAB IN ELDERLY IBD PATIENTS: A REAL-LIFE MULTICENTRIC COHORT STUDY

IBD (Posters)  et al.

IS LONGER TIME BETWEEN IBD DIAGNOSIS AND FIRST BIOLOGIC INITIATION LEADING TO HIGHER DISEASE SEVERITY AND MORE HOSPITALIZATIONS IN ITALY AND THE UNITED KINGDOM? A COMPARISON TO SIMILAR METRICS IN THE UNITED STATES
IS LONGER TIME BETWEEN IBD DIAGNOSIS AND FIRST BIOLOGIC INITIATION LEADING TO HIGHER DISEASE SEVERITY AND MORE HOSPITALIZATIONS IN ITALY AND THE UNITED KINGDOM? A COMPARISON TO SIMILAR METRICS IN THE UNITED STATES

IBD (Posters)

MRI FOLLOW UP IN ACTIVE PERIANAL FISTULIZING CROHN’S DISEASE REFRACTORY TO ANTI-TUMOR NECROSIS FACTOR THERAPY RECEIVING USTEKINUMAB
MRI FOLLOW UP IN ACTIVE PERIANAL FISTULIZING CROHN’S DISEASE REFRACTORY TO ANTI-TUMOR NECROSIS FACTOR THERAPY RECEIVING USTEKINUMAB

IBD (Posters)  et al.

CROHN’S DISEASE ASSOCIATED FIBROSIS MODULATES THE EXPRESSION OF COLLAGEN RECEPTORS
CROHN’S DISEASE ASSOCIATED FIBROSIS MODULATES THE EXPRESSION OF COLLAGEN RECEPTORS

IBD (Posters)  et al.

CLINICAL CHARACTERISTICS ASSOCIATED WITH BIOCHEMICAL REMISSION THREE MONTHS AFTER DIAGNOSIS OF CROHN’S DISEASE
CLINICAL CHARACTERISTICS ASSOCIATED WITH BIOCHEMICAL REMISSION THREE MONTHS AFTER DIAGNOSIS OF CROHN’S DISEASE

IBD (Posters)  et al.

RISANKIZUMAB INDUCTION THERAPY PROVIDES EARLY SYMPTOM IMPROVEMENTS IN ABDOMINAL PAIN AND STOOL FREQUENCY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE: RESULTS FROM TWO PHASE 3 INDUCTION STUDIES
RISANKIZUMAB INDUCTION THERAPY PROVIDES EARLY SYMPTOM IMPROVEMENTS IN ABDOMINAL PAIN AND STOOL FREQUENCY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE: RESULTS FROM TWO PHASE 3 INDUCTION STUDIES

IBD (Posters)  et al.

CLINICAL AND ULTRASONOGRAPHIC ENTHESITIS IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH AND WITHOUT PSORIASIS
CLINICAL AND ULTRASONOGRAPHIC ENTHESITIS IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH AND WITHOUT PSORIASIS

IBD (Posters)  et al.

SUCCINATE RECEPTOR (SUCNR1) MEDIATES LEUKOCYTE-ENDOTHELIAL CELL INTERACTIONS INDUCED BY TNF?
SUCCINATE RECEPTOR (SUCNR1) MEDIATES LEUKOCYTE-ENDOTHELIAL CELL INTERACTIONS INDUCED BY TNF?

IBD (Posters)  et al.

ASSESSEMENT OF CUMULATIVE BOWEL DAMAGE USING LEMANN INDEX AND MARIA SCORE IN SURGICALLY NAIVE PATIENTS WITH CROHN'S DISEASE
ASSESSEMENT OF CUMULATIVE BOWEL DAMAGE USING LEMANN INDEX AND MARIA SCORE IN SURGICALLY NAIVE PATIENTS WITH CROHN'S DISEASE

IBD (Posters)  et al.

CLINICAL CHARACTERISTICS ASSOCIATED WITH BIOCHEMICAL REMISSION THREE MONTHS AFTER DIAGNOSIS OF ULCERATIVE COLITIS
CLINICAL CHARACTERISTICS ASSOCIATED WITH BIOCHEMICAL REMISSION THREE MONTHS AFTER DIAGNOSIS OF ULCERATIVE COLITIS

IBD (Posters)  et al.

FECAL CALPROTECTIN: ROLE IN MONITORING ILEAL CROHN'S DISEASE ACTIVITY DETECTED BY INTESTINAL ULTRASONOGRAPHY
FECAL CALPROTECTIN: ROLE IN MONITORING ILEAL CROHN'S DISEASE ACTIVITY DETECTED BY INTESTINAL ULTRASONOGRAPHY

IBD (Posters)  et al.

PROACTIVE THERAPEUTIC DRUG MONITORING OF ANTI-TNF AGENTS IS ASSOCIATED WITH HIGHER MUCOSAL HEALING RATES IN CROHN'S DISEASE
PROACTIVE THERAPEUTIC DRUG MONITORING OF ANTI-TNF AGENTS IS ASSOCIATED WITH HIGHER MUCOSAL HEALING RATES IN CROHN'S DISEASE

IBD (Posters)  et al.

INFLUENCE OF COVID-19 ON INFLAMMATORY BOWEL DISEASE PATIENTS AND BIOLOGICAL TREATMENT
INFLUENCE OF COVID-19 ON INFLAMMATORY BOWEL DISEASE PATIENTS AND BIOLOGICAL TREATMENT

IBD (Posters)  et al.

Item 461 - 480 / 568
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24
25 26 27 28 29